美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Tvardi Therapeutics Inc

17.47

+0.43092.53%

盘后：17.470.00000.00%17:00 EDT

成交量：1.03万

成交额：17.68万

市值：1.63亿

市盈率：-1.12

高：18.75

开：16.10

低：15.80

收：17.04

数据加载中...

总览公司新闻公告

公司资料

公司名字：

Tvardi Therapeutics Inc

交易所：

NASDAQ

成立时间：

2017

员工人数：

- -

公司地址：

3 Sugar Creek Center Boulevard,Suite 525,Sugar Land,Texas,United States

官网：

http://tvarditherapeutics.com

邮编：

77478

电话：

传真：

- -

简介：

Tvardi Therapeutics, Inc.于2017年12月20日注册成立，是一家总部位于德克萨斯州休斯顿的特拉华州公司。该公司是一家临床阶段的生物制药公司，专注于开发针对STAT3的新型口服小分子疗法，以治疗具有重大未满足需求的纤维化驱动疾病。基于其创始人的开创性工作和对转录因子STAT3的深刻理解，该公司设计了一种创新方法来直接抑制STAT3，这是一种经过高度验证但在历史上是不可药物的靶点。利用这些专业知识，该公司正在开发具有差异化作用机制和方便的口服给药的STAT3抑制剂管道。该公司的主要候选产品TTI-101目前处于2期临床开发阶段，用于治疗纤维化驱动的疾病，初步重点是特发性肺纤维化、IPF和肝细胞癌、HCC。

董事

名称

职位

Derek Chalmers

Director,President and Chief Executive Officer

Dean Slagel

董事

Harrison M. Bains, Jr.

董事

Jeffrey L. Ives

董事

Martin Vogelbaum

董事

股东

名称

职位

Derek Chalmers

Director,President and Chief Executive Officer

Josef Schoell

Treasurer, Chief Financial Officer

Frederique Menzaghi

Vice President - Research and Development

Joseph Stauffer

Chief Medical Officer

Michael E. Lewis

Chief Scientific Advisor

Scott M. Terrillion

General Counsel, Secretary

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/TVRD/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":17.47,"timestamp":1745265600000,"preClose":17.0391,"halted":0,"volume":10312,"hourTrading":{"tag":"盘后","latestPrice":17.47,"preClose":17.47,"latestTime":"17:00 EDT","volume":23,"amount":394.22,"timestamp":1745269215008},"delay":0,"floatShares":3316400,"shares":9355542,"eps":-15.531682,"marketStatus":"已收盘","change":0.4309,"latestTime":"04-21 16:00:00 EDT","open":16.1,"high":18.75,"low":15.8,"amount":176807.757712,"amplitude":0.173131,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-15.531682,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1745308800000},"marketStatusCode":5,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":17.0391,"preHourTrading":{"tag":"盘前","latestPrice":14.7,"preClose":17,"latestTime":"08:56 EDT","volume":46,"amount":588.9500059999999,"timestamp":1745240205791},"postHourTrading":{"tag":"盘后","latestPrice":17.47,"preClose":17.47,"latestTime":"17:00 EDT","volume":23,"amount":394.22,"timestamp":1745269215008},"volumeRatio":0.256204},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":3316400,"roa":"--","roe":"--","lyrEps":-15.531682,"volumeRatio":0.256204,"shares":9355542,"dividePrice":0,"high":18.75,"amplitude":0.173131,"preClose":17.0391,"low":15.8,"week52Low":8.1252,"pbRate":"--","week52High":31.32,"institutionHeld":0,"latestPrice":17.47,"eps":-15.531682,"divideRate":0,"volume":10312,"delay":0,"ttmEps":-15.531682,"open":16.1,"prevYearClose":18.36,"prevWeekClose":17.0391,"prevMonthClose":15.21,"prevQuarterClose":15.21,"fiveDayClose":14.7,"twentyDayClose":17.1,"sixtyDayClose":15.18},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":570288312,"yearFounded":2017,"address":"3 Sugar Creek Center Boulevard,Suite 525,Sugar Land,Texas,United States","zipCode":"77478","officePhone":"832-413-1362"},"stockCompanyDetail":{"websiteUrl":"http://tvarditherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1675},{"period":"1month","weight":0.0923},{"period":"3month","weight":0.2214},{"period":"6month","weight":0.7854},{"period":"1year","weight":-0.3533},{"period":"ytd","weight":-0.0719}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tvardi Therapeutics, Inc.于2017年12月20日注册成立，是一家总部位于德克萨斯州休斯顿的特拉华州公司。该公司是一家临床阶段的生物制药公司，专注于开发针对STAT3的新型口服小分子疗法，以治疗具有重大未满足需求的纤维化驱动疾病。基于其创始人的开创性工作和对转录因子STAT3的深刻理解，该公司设计了一种创新方法来直接抑制STAT3，这是一种经过高度验证但在历史上是不可药物的靶点。利用这些专业知识，该公司正在开发具有差异化作用机制和方便的口服给药的STAT3抑制剂管道。该公司的主要候选产品TTI-101目前处于2期临床开发阶段，用于治疗纤维化驱动的疾病，初步重点是特发性肺纤维化、IPF和肝细胞癌、HCC。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.042039},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019771},{"month":3,"riseRate":0.583333,"avgChangeRate":0.021822},{"month":4,"riseRate":0.25,"avgChangeRate":-0.091823},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.001774},{"month":6,"riseRate":0.636364,"avgChangeRate":-0.002947},{"month":7,"riseRate":0.454545,"avgChangeRate":0.089214},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.002014},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.067808},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.031996},{"month":11,"riseRate":0.545455,"avgChangeRate":0.051738},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.02182}],"exchange":"NASDAQ","name":"Tvardi Therapeutics Inc","nameEN":"Tvardi Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":{"directors":[{"name":"Derek Chalmers","position":"Director,President and Chief Executive Officer"},{"name":"Dean Slagel","position":"董事"},{"name":"Harrison M. Bains, Jr.","position":"董事"},{"name":"Jeffrey L. Ives","position":"董事"},{"name":"Martin Vogelbaum","position":"董事"}],"executives":[{"name":"Derek Chalmers","position":"Director,President and Chief Executive Officer"},{"name":"Josef Schoell","position":"Treasurer, Chief Financial Officer"},{"name":"Frederique Menzaghi","position":"Vice President - Research and Development"},{"name":"Joseph Stauffer","position":"Chief Medical Officer"},{"name":"Michael E. Lewis","position":"Chief Scientific Advisor"},{"name":"Scott M. Terrillion","position":"General Counsel, Secretary"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-16","symbol":"TVRD","defaultRemindTime":1744810200000,"type":"split","dateTimestamp":1744776000000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-03-11","symbol":"TVRD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-12-31","symbol":"TVRD","defaultRemindTime":1735655400000,"type":"split","dateTimestamp":1735621200000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2024-11-14","symbol":"TVRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.25,"name":null,"time":"盘后","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2024-08-14","symbol":"TVRD","fiscalQuarterEnding":"2024/06","expectedEps":-0.29,"name":null,"time":"盘后","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{}}}